tbuckley/cabot-search huggingface dataset:
Studies of Hydrocephalus Associated With Long-term Spaceflight May Provide New Insights Into Cerebrospinal Fluid Flow Dynamics Here on Earth
Authors: Donna R. Roberts, Lonnie G. Petersen
Journal: JAMA Neurology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Pattern of Brain Activity Linked to Low Mood in People With High Trait Anxiety
Authors: Tracy Hampton
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Exposure to indoor endocrine‐disrupting chemicals and childhood asthma and obesity
Authors: Inês Paciência, João Cavaleiro Rufo, Diana Silva, Carla Martins, Francisca Mendes, Mariana Farraia, Luís Delgado, Eduardo de Oliveira Fernandes, Patrícia Padrão, Pedro Moreira, Milton Severo, Henrique Barros, André Moreira
Journal: Allergy (2019)

Indoor air contaminants may act as endocrine-disrupting chemicals (EDCs). However, to what extent these contaminants affect health is poorly known. We aimed to assess the association between EDCs exposure and asthma, respiratory symptoms and obesity in schoolchildren.Data from a cross-sectional analysis of 815 participants from 20 schools in Porto, Portugal, were analysed. Symptoms were assessed, asthma was defined on lung function, and airway reversibility and body mass index (BMI) were calculated. The concentrations of 13 volatile organic compounds and 2 aldehydes identified as EDCs were measured in 71 classrooms throughout 1 week. Principal component analysis (PCA) was used to assess the effect of co-exposure. Associations were estimated by regression coefficients using linear and logistic regression models.Increased individual and combined EDCs levels were found in classrooms having more children with asthma and obesity. Higher levels of hexane, styrene, cyclohexanone, butylated hydroxytoluene and 2-butoxyethanol were associated with obesity, and higher levels of cyclohexanone were associated with increased child BMI. Toluene, o-xylene, m/p-xylene and ethylbenzene were significantly associated with nasal obstruction. A positive association was found between PC1 and the risk of obese asthma (OR = 1.43, 95% CI 1.01, 1.98) and between PC2 and overweight (OR = 1.51, 95% CI 1.28, 1.79). PC1 and PC2 were also associated with nasal obstruction, and PC2 was associated with breathing difficulties and lean body mass, although EDCs concentrations were low.Our findings further support the role of EDCs in asthma and obesity development. Moreover, even low levels of indoor exposure may influence the risk of asthma, respiratory symptoms and obesity.
Role of Periostin in Brazilian Patients with Aspirin Exacerbated Respiratory Disease
Authors: Julianne Alves Machado, Daniel L. Cordeiro, Thais Nociti Mendonca, Marcelo Leite, Ricardo Demarco, Ricardo Lessa, Adriana Murashima, Leilane Nogueira, Marina Dias, Adriana S. Moreno, Wilma Lima, Luisa Karla P. Arruda
Journal: Journal of Allergy and Clinical Immunology (2019)
Abstract 16912: Early Intracoronary Delivery of Recombinant TIMP-3 Following Myocardial Infarction Markedly Reduces MMP Activation in the Heart
Authors: Stephanie L Thorn, Shayne C Barlow, Attila Feher, Eva Romito, Mitchel Stacy, Heather Doviak, Julia Jacobs, Kia Zellars, Aarif Khakoo, TaeWeon Lee, Francis G Spinale, Albert Sinusas
Journal: Circulation (2017)

Introduction: In the setting of acute infarction, early percutaneous coronary intervention (PCI) has immense therapeutic value in reducing infarct size, subsequent late left ventricle (LV) remodeling, and mortality. Following ischemia-reperfusion (I/R) there is early induction of proteolytic enzymes, matrix metalloproteinases (MMPs), which are inhibited by endogenous tissue inhibitors of the MMPs (TIMPs). This MMP/TIMP balance is critical in the modulation of the degree of adverse LV remodeling. Hypothesis: To determine the efficacy of intracoronary delivery of rTIMP-3 in reducing MMP activation in the infarct zone, in relation to changes in perfusion and function. Methods: I/R was induced in pigs by a 90 min LAD balloon occlusion. rTIMP-3 (1.0 mg/kg) was infused over 4 min through the lumen of the balloon (n=5), or saline for controls (n=4) prior to reperfusion. In vivo SPECT/CT imaging was performed 3 day post I/R with an MMP targeted radiotracer (99mTc-RP805, 40-60 mCi) to determine early MMP activatio...
Abstract 16968: A Randomized Trial of the Effects of Insulin and Metformin on Myocardial Stress in Patients With Type II Diabetes Mellitus
Authors: Pratyaksh K Srivastava, Aruna D Pradhan, Nancy R Cook, Paul M Ridker, Brendan M Everett
Journal: Circulation (2017)

Background: Myocardial stress, as measured by N-terminal pro-B-type natriuretic peptide (NT-proBNP), is related to glycemic control in patients with type 2 diabetes (T2D), and is a strong predictor of adverse cardiovascular outcome. Our objective was to determine, in a randomized fashion, whether anti-hyperglycemic therapy improves myocardial stress in patients with T2D. Methods: We randomized, in a 2x2 factorial fashion, 438 patients with T2D to insulin glargine, metformin, the combination, or placebo and measured changes in NT-proBNP after 12 weeks of therapy. The primary comparison was insulin vs. no insulin and metformin vs. no metformin. Results: At baseline, the median (Q1-Q3) NT-proBNP plasma concentration was 35.4 (15.7-86.3) ng/l and did not differ by randomized treatment group (p=0.40). The adjusted (95% CI) change in NT-proBNP concentration was 20.7% (7.9 to 35.0) in the insulin arm compared with 0.2% (-10.8 to 12.5) in the no-insulin arm (P=0.03 for comparison). In the metformin arm, the adjus...
Double-Unit Cord Blood (CB) Transplantation with Haplo-Identical CD34+ Cells (haplo-dCBT) May Speed Neutrophil Recovery Although Successful Bridging Is Contingent on Close Haplo-Winning CB Unit HLA-Match
Authors: Ioannis Politikos, Sean M Devlin, Christopher Mazis, Molly Maloy, Kristine Naputo, Aishat Olaide Afuye, Valkal Bhatt, Andromachi Scaradavou, Richard J. O'Reilly, Scott T Avecilla, Hugo R. Castro-Malaspina, Christina Cho, Parastoo B. Dahi, Sergio Giralt, Boglarka Gyurkocza, Katharine C. Hsu, Ann A. Jakubowski, Esperanza B. Papadopoulos, Miguel-Angel Perales, Craig S. Sauter, Michael Scordo, Brian C. Shaffer, Gunjan L. Shah, Roni Tamari, Marcel R.M. van den Brink, James W. Young, Doris Ponce, Juliet Barker
Journal: Blood (2018)
Association of Electronic Cigarette Use With Subsequent Initiation of Tobacco Cigarettes in US Youths
Authors: Kaitlyn M. Berry, Jessica L. Fetterman, Emelia J. Benjamin, Aruni Bhatnagar, Jessica L. Barrington-Trimis, Adam M. Leventhal, Andrew Stokes
Journal: JAMA Network Open (2019)

The use of electronic cigarettes (e-cigarettes) and other noncigarette tobacco products may increase the odds of cigarette initiation, even among low-risk youths.To evaluate the associations of prior e-cigarette use and other tobacco product use with subsequent cigarette initiation within 2 years of follow-up.In this prospective cohort study, data from waves 1 through 3 of the Population Assessment of Tobacco and Health Study (2013-2016) were used to assess youths aged 12 to 15 years who had never used cigarettes, e-cigarettes, or other tobacco products at wave 1. This was a nationally representative study of the US population. Data analysis was conducted in 2018.First noncigarette tobacco product used (none, e-cigarette, or other tobacco product) between wave 1 and wave 3.Ever cigarette use and current cigarette use at wave 3.In the sample (N = 6123), respondents were 49.5% female; 54.1% non-Hispanic, white; and the mean (SD) age was 13.4 (1.2) years. Of these, 8.6% reported e-cigarettes as their first tobacco product, while 5.0% reported using another noncigarette product first; 3.3% reported using cigarettes first. Cigarette use at wave 3 was higher among prior e-cigarette users (20.5%) compared with youths with no prior tobacco use (3.8%). Prior e-cigarette use was associated with more than 4 times the odds of ever cigarette use (odds ratio, 4.09; 95% CI, 2.97-5.63) and nearly 3 times the odds of current cigarette use (odds ratio, 2.75; 95% CI, 1.60-4.73) compared with no prior tobacco use. Prior use of other tobacco products was similarly associated with subsequent ever cigarette use (OR, 3.84; 95% CI, 2.63-5.63) and current cigarette use (OR, 3.43; 95% CI, 1.88-6.26) compared with no prior tobacco use. The association of prior e-cigarette use with cigarette initiation was stronger among low-risk youths (OR, 8.57; 95% CI, 3.87-18.97), a pattern not seen for prior other product use. Over the 2 years between 2013 and 2014 and 2015 and 2016, 21.8% of new cigarette ever use (178 850 youths) and 15.3% of current cigarette use (43 446 youths) among US youths aged 12 to 15 years may be attributable to prior e-cigarette use.This study's findings support the notion that e-cigarette use is associated with increased risk for cigarette initiation and use, particularly among low-risk youths. At the population level, the use of e-cigarettes may be a contributor to the initiation of cigarette smoking among youths.
Ethical Issues Involved in Grateful Patient Fundraising—Reply
Authors: Megan E. Collins, Steven A. Rum, Jeremy Sugarman
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Authors: Alan Menter, Bruce E. Strober, Daniel H. Kaplan, Dario Kivelevitch, Elizabeth Farley Prater, Benjamin Stoff, April W. Armstrong, Cody Connor, Kelly M. Cordoro, Dawn M.R. Davis, Boni E. Elewski, Joel M. Gelfand, Kenneth B. Gordon, Alice B. Gottlieb, Arthur Kavanaugh, Matthew Kiselica, Neil J. Korman, Daniela Kroshinsky, Mark Lebwohl, Craig L. Leonardi, Jason Lichten, Henry W. Lim, Nehal N. Mehta, Amy S. Paller, Sylvia L. Parra, Arun L. Pathy, Reena N. Rupani, Michael Siegel, Emily B. Wong, Jashin J. Wu, Vidhya Hariharan, Craig A. Elmets
Journal: Journal of the American Academy of Dermatology (2019)
“Maximum tolerated dose” vs “fixed low‐dose” hydroxyurea for treatment of adults with sickle cell anemia
Authors: Titilola S. Akingbola, Bamidele O. Tayo, Chinedu A. Ezekekwu, Omowunmi Sonubi, Xu Zhang, Santosh L. Saraf, Robert Molokie, Lewis L. Hsu, Jin Han, Richard S. Cooper, Victor R. Gordeuk
Journal: American Journal of Hematology (2019)

Maximum tolerated dose" vs "fixed low-dose" hydroxyurea for treatment of adults with sickle cell anemiaTo the Editor:Despite evidence that hydroxyurea is effective for sickle cell anemia (SCA), implementation of the "maximum tolerated dose" regimen in adults is poor. 1 We recently reported a study of "fixed low-dose" hydroxyurea (500 mg/day) for adults with SCA in Ibadan, Nigeria. 2Here we compare the outcomes of "fixed low-dose" hydroxyurea in Nigeria with "maximum tolerated dose" hydroxyurea in the United States and Canada as reported in the Multicenter Study of Hydroxyurea (MSH). 3,4The MSH was the seminal trial conducted in the 1990s that led to FDA approval of hydroxyurea for SCA.Responses to "fixed low-dose" and "maximum tolerated dose" hydroxyurea appear to be similar.We propose that these two regimens be compared in a prospective trial in adults with SCA.Hydroxyurea for SCA increases hemoglobin F and reduces pain crises, acute chest syndrome and blood transfusions. 5The agent is initiated at 15 mg/kg/day in adults followed by dose escalations up to 35 mg/kg/day if tolerated-the "maximum tolerated dose" approach of the MSH. 3,4Doses in this range may enhance survival, 6 however, neutropenia and thrombocytopenia are limitations to achieving maximal dose, frequent blood count monitoring is required, and treatment interruption is usually necessary. 4,5This limits the use of hydroxyurea in parts of Africa where frequent blood monitoring is not feasible. 7In the United States and United Kingdom, the complexity and need for frequent monitoring of the recommended "maximum tolerated dose" regimen cause primary care providers to hesitate to prescribe hydroxyurea 8 and create barriers to compliance. 9In the original MSH study, pain crises in SCA adults decreased during the first 12 weeks of hydroxyurea 15 mg/kg/day before dose escalation and before maximal increase in F-cells.
Abstract 14230: A Methodology for Ascertaining Acute Limb Ischemia in Medicare Claims
Authors: Marc P Bonaca, Jeremy R Van’t Hof, Eric D Weinhandl, David A Morrow, Niki C Oldenburg, Monica Chase, Joshua A Beckman
Journal: Circulation (2017)

Introduction: Acute limb ischemia (ALI) is a highly morbid, limb-threatening event recently incorporated into trials of antithrombotic therapies in peripheral artery disease (PAD). In the absence of specific codes, determining real world rates of ALI is challenging and remains an unmet need. Hypothesis: We hypothesized that a review of endpoint definitions and strictly adjudicated ALI events from a randomized clinical trial could be used to develop an algorithm to estimate ALI rates in administrative datasets. Methods: We reviewed dossiers from adjudicated ALI events from the TRA2•P-TIMI 50 trial and identified diagnoses and clinical elements with high frequency in ALI vs. non-ALI events. Diagnoses were reviewed by vascular experts against ICD-9 diagnosis codes and divided into groups based on discrimination for ALI (narrow, intermediate, broad). Common clinical elements were identified for development of an algorithm that was applied in a random sample of Medicare beneficiaries with PAD. Results: A total...
Interventions to Prevent Perinatal Depression
Authors: Susan J. Curry, Alex H. Krist, Douglas K. Owens, Michael J. Barry, Aaron B. Caughey, Karina W. Davidson, Chyke A. Doubeni, John W. Epling, David C. Grossman, Alex R. Kemper, Martha Kubik, C. Seth Landefeld, Carol M. Mangione, Michael Silverstein, Melissa A. Simon, Chien-Wen Tseng, John B. Wong
Journal: JAMA (2019)

<h3>Importance</h3> Perinatal depression, which is the occurrence of a depressive disorder during pregnancy or following childbirth, affects as many as 1 in 7 women and is one of the most common complications of pregnancy and the postpartum period. It is well established that perinatal depression can result in adverse short- and long-term effects on both the woman and child. <h3>Objective</h3> To issue a new US Preventive Services Task Force (USPSTF) recommendation on interventions to prevent perinatal depression. <h3>Evidence Review</h3> The USPSTF reviewed the evidence on the benefits and harms of preventive interventions for perinatal depression in pregnant or postpartum women or their children. The USPSTF reviewed contextual information on the accuracy of tools used to identify women at increased risk of perinatal depression and the most effective timing for preventive interventions. Interventions reviewed included counseling, health system interventions, physical activity, education, supportive interventions, and other behavioral interventions, such as infant sleep training and expressive writing. Pharmacological approaches included the use of nortriptyline, sertraline, and omega-3 fatty acids. <h3>Findings</h3> The USPSTF found convincing evidence that counseling interventions, such as cognitive behavioral therapy and interpersonal therapy, are effective in preventing perinatal depression. Women with a history of depression, current depressive symptoms, or certain socioeconomic risk factors (eg, low income or young or single parenthood) would benefit from counseling interventions and could be considered at increased risk. The USPSTF found adequate evidence to bound the potential harms of counseling interventions as no greater than small, based on the nature of the intervention and the low likelihood of serious harms. The USPSTF found inadequate evidence to assess the benefits and harms of other noncounseling interventions. The USPSTF concludes with moderate certainty that providing or referring pregnant or postpartum women at increased risk to counseling interventions has a moderate net benefit in preventing perinatal depression. <h3>Conclusions and Recommendation</h3> The USPSTF recommends that clinicians provide or refer pregnant and postpartum persons who are at increased risk of perinatal depression to counseling interventions. (B recommendation)
Generation of pulmonary neuroendocrine cells and SCLC-like tumors from human embryonic stem cells
Authors: Huanhuan Joyce Chen, Asaf Poran, Arun M. Unni, Sarah Xuelian Huang, Olivier Elemento, Hans-Willem Snoeck, Harold Varmus
Journal: The Journal of Experimental Medicine (2019)

Cancer models based on cells derived from human embryonic stem cells (hESCs) may reveal why certain constellations of genetic changes drive carcinogenesis in specialized lineages. Here we demonstrate that inhibition of NOTCH signaling induces up to 10% of lung progenitor cells to form pulmonary neuroendocrine cells (PNECs), putative precursors to small cell lung cancers (SCLCs), and we can increase PNECs by reducing levels of retinoblastoma (RB) proteins with inhibitory RNA. Reducing levels of TP53 protein or expressing mutant KRAS or EGFR genes did not induce or expand PNECs, but tumors resembling early-stage SCLC grew in immunodeficient mice after subcutaneous injection of PNEC-containing cultures in which expression of both RB and TP53 was blocked. Single-cell RNA profiles of PNECs are heterogeneous; when RB levels are reduced, the profiles resemble those from early-stage SCLC; and when both RB and TP53 levels are reduced, the transcriptome is enriched with cell cycle–specific RNAs. Our findings suggest that genetic manipulation of hESC-derived pulmonary cells will enable studies of this recalcitrant cancer.
Ruxolitinib for the Treatment of Inadequately Controlled Polycythemia Vera without Splenomegaly: 156-Week Follow-up from the Phase 3 Response-2 Study
Authors: Francesco Passamonti, Francesca Palandri, Guray Saydam, Giulia Benevolo, Miklos Egyed, Jeannie Callum, Timothy Devos, Serdar Sivgin, Paola Guglielmelli, Alessandro M. Vannucchi, Caroline Bensasson, Albert Kandra, Juliane Morando, Martin Griesshammer
Journal: Blood (2018)
Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial
Authors: Vivek Subbiah, Pete M. Anderson, Kalevi Kairemo, Kenneth Hess, Winston W. Huh, Vinod Ravi, Najat C. Daw, Neeta Somaiah, Joseph A. Ludwig, Robert S. Benjamin, Sant Chawla, David S. Hong, Funda Meric-Bernstam, Gregory Ravizzini, Eugenie Kleinerman, Homer Macapinlac, Eric Rohren
Journal: Clinical Cancer Research (2019)

The prognosis of metastatic osteosarcoma continues to be poor. We hypothesized that alpha-emitting, bone-targeting radium 223 dichloride (223RaCl2) can be safely administered to patients with osteosarcoma and that early signals of response or resistance can be assessed by quantitative and qualitative correlative imaging studies and biomarkers.A 3+3 phase I, dose-escalation trial of 223RaCl2 (50, 75, and 100 kBq/kg) was designed in patients with recurrent/metastatic osteosarcoma aged ≥15 years. Objective measurements included changes in standardized uptake values of positron emission tomography (PET; 18FDG and/or NaF-18) and single-photon emission CT/CT (99mTc-MDP) as well as alkaline phosphatase and bone turnover markers at baseline, midstudy, and the end of the study.Among 18 patients enrolled (including 15 males) aged 15-71 years, tumor locations included spine (n = 12, 67%), pelvis (n = 10, 56%), ribs (n = 9, 50%), extremity (n = 7, 39%), and skull (n = 2, 11%). Patients received 1-6 cycles of 223RaCl2; cumulative doses were 6.84-57.81 MBq. NaF PET revealed more sites of metastases than did FDG PET. One patient showed a metabolic response on FDG PET and NaF PET. Four patients had mixed responses, and one patient had a response in a brain metastasis. Bronchopulmonary hemorrhage from Grade 3 thrombocytopenia (N = 1) was a DLT. The median overall survival time was 25 weeks.The first evaluation of the safety and efficacy of an alpha particle in high-risk osteosarcoma shows that the recommended phase II dose for 223RaCl2 in osteosarcoma is 100 kBq/kg monthly (twice the dose approved for prostate cancer), with minimal hematologic toxicity, setting the stage for combination therapies.
3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups
Authors: Natasha Szuber, Mythri Mudireddy, Maura Nicolosi, Domenico Penna, Rangit Vallapureddy, Terra L. Lasho, Christy Finke, Kebede H. Begna, Michelle A. Elliott, C. Christopher Hook, Alexandra Wolanskyj, Mrinal M. Patnaik, Curtis A. Hanson, Rhett P. Ketterling, Shireen Sirhan, Animesh Pardanani, Naseema Gangat, Lambert Busque, Ayalew Tefferi
Journal: Blood (2018)